Groundbreaking Therapies
IMPROVING THE LIVES OF THOSE SUFFERING FROM CENTRAL NERVOUS SYSTEM DISORDERS.
Groundbreaking Therapies
IMPROVING THE LIVES OF THOSE SUFFERING FROM CENTRAL NERVOUS SYSTEM DISORDERS.
Fast Track To Commercialization
Specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders
PRODUCT pipeline
Four drug candidates in clinical trials with applications for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, Autism Spectrum Disorder, and two in pre-clinical studies for Status Epilepticus, and Chronic Pain.
OUTSTANDING MANAGENT TEAM & SCIENTIFIC ADVISORY BOARD
SciSparc is managed by an established team with a proven track record of execution in drug development, working in concert with a world class, award-winning, scientific advisory board chaired by the renowned Professor Raphael Mechoulam. Together they bring decades of experience in biochemistry and pharmacology, research and development, manufacturing, international distribution, clinical and regulatory affairs, as well as financial acumen to the SciSparc operation.
